We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Monday that its pancreatic-cancer drug Lynparza has been approved by the U.S. Food and Drug Administration as a first-line maintenance treatment for metastatic pancreatic cancer.
The British drug maker said the drug has reduced the risk of disease progression or death by 47% in adult patients whose disease has not advanced on at least 16 weeks, as the results from the pivotal Phase 3 POLO trial showed.
The London-listed company said Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer.
"Metastatic pancreatic cancer patients have been waiting a long time for new therapy options for their devastating disease. Today's approval of Lynparza provides an exciting new treatment option for patients," Julie Fleshman, President and CEO of Pancreatic Cancer Action Network, said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 30, 2019 02:27 ET (07:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
